Table 1 Multivariable analysis of relapse-free and overall survival in the cohorts of laryngeal squamous cancer patients treated with Cetuximab + radio-therapy (RT) or upfront surgery + radio-chemio-therapy (RCT)
Covariates: | N | Cetuximab + RT | N | Up-front surgery + RCT | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Relapse-free survival | Overall survival | Relapse-free survival | Overall survival | |||||||||||
RR | C.I. 95% | p | RR | C.I. 95% | p | RR | C.I. 95% | p | RR | C.I. 95% | p | |||
Age (risk per year) | 66 | 0.96 | 0.9–1.0 | 0.045 | 0.93 | 0.9–1.0 | 0.11 | 66 | 0.97 | 0.9–1.0 | 0.20 | 0.96 | 1.0–1.1 | 0.12 |
Site | ||||||||||||||
Glottic | 47 | 1 | 1 | 49 | 1 | 1 | ||||||||
Transglottic | 19 | 3.24 | 1.4–7.5 | 0.006 | 1.87 | 0.4–8.8 | 0.43 | 17 | 1.29 | 0.4–2.9 | 0.92 | 1.15 | 0.4–3.3 | 0.79 |
T | ||||||||||||||
2 | 36 | 1 | 1 | 31 | 1 | 1 | ||||||||
3–4 | 30 | 0.64 | 0.1–2.8 | 0.55 | 0.64 | 0.09–4.6 | 0.65 | 35 | 3.39 | 0.4–29.7 | 0.27 | 1.19 | 0.2–6.7 | 0.79 |
Stage | ||||||||||||||
II | 29 | 1 | 1 | 23 | 1 | 1 | ||||||||
III–IV | 37 | 1.26 | 0.3–6.0 | 0.77 | 11.3 | 0.8–165.7 | 0.08 | 43 | 0.30 | 0.03–4.0 | 0.30 | 1.03 | 0.1–7.1 | 0.98 |
N | ||||||||||||||
Negative | 50 | 1 | 1 | 56 | 1 | 1 | ||||||||
Positive | 16 | 0.77 | 0.2–2.6 | 0.67 | 1.11 | 0.2–5.0 | 0.89 | 10 | 4.35 | 1.5–12.8 | 0.008 | 4.18 | 1.2–14.2 | 0.022 |
HER-1 | ||||||||||||||
Negative | 24 | 1 | 1 | 37 | 1 | 1 | ||||||||
Positive | 42 | 2.63 | 0.9–7.4 | 0.062 | 8.33 | 0.9–76.3 | 0.04 | 29 | 6.11 | 2.1–17.15 | 0.001 | 6.43 | 1.9–22.3 | 0.003 |
HER-2 | ||||||||||||||
Negative | 33 | 1 | 1 | 29 | 1 | 1 | ||||||||
Positive | 33 | 1.04 | 0.4–2.7 | 0.94 | 3.44 | 0.5–24.0 | 0.21 | 37 | 1.87 | 0.7–5.1 | 0.23 | 1.87 | 0.6–5.9 | 0.28 |
HER-3 | ||||||||||||||
Negative | 50 | 1 | 1 | 47 | 1 | 1 | ||||||||
Positive | 16 | 0.17 | 0.04–0.69 | 0.013 | 0.03 | 0.002–0.5 | 0.012 | 19 | 0.15 | 0.04–0.65 | 0.010 | 0.13 | 0.02–0.7 | 0.019 |
Concordance index | 0.77 | 0.83 | 0.78 | 0.78 | ||||||||||